1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
2. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280–285.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
4. Patel A, MacMahon S, Chalmers J, et al; for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
5. The Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–9.
6. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM. 2005;353(25):2643–53. doi:10.1056/NEJMoa052187.
7. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): Clinical and therapeutic implications for type 2 diabetes. British J Clinical Pharm. 1999;48(5):643–8. doi:10.1046/j.1365-2125.1999.00092.x.
8. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. The Cochrane Library 2013.
9. Malmberg K, Rydén L, Wedel H, et al; for the DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J. 2005;26:650–661.
10. Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: Cohort study. BMJ. 2008;337:a236.
11. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163:1306–1316.
12. Gerstein HC, Miller ME, Byington RP, et al. Action to control cardiovascular risk in diabetes (ACCORD) study group: Effects of intensive glucose lowering in type 2 diabetes. NEJM. 2008;358:2545-59.
13. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEJM. 2008;358:2560-72.
14. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM. 2008;359:1577-89.
15. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA. 2003;290:486–494.
16. Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol. 2007;27:2456–2462.
17. Iijima R, Nakajima R, Sugi K, Nakamura M. Improvement of postprandial hyperglycemia has a positive impact on epicardial flow of entire coronary tree in acute coronary syndromes patients. Circ J. 2007;71:1079–1085.
18. Dungan KM, Buse JB, Largay J, et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214–9. doi:10.2337/dc06-1910.
19. Kishimoto M, Yamasaki Y, Kubota M, et al. 1,5-anhydro-d-glucitol evaluated daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 1995;18:1156–9.
20. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effect of short- and long-term simvastatin treatment. Circulation. 2002;106:1211-8.
21. American Diabetes Association. Postprandial blood glucose. American diabetes association. Diabetes Care. 2001;24:775-8.
22. Meigs JB, Nathan DM, D’Agostino RB Sr, et al. Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care. 2002;25:1845-50.
23. Dworacka M, Winiarska H. The application of plasma 1,5-anhydro-d-glucitol for monitoring type 2 diabetic patients. Disease Markers. 2005;21(3):127–32. doi:10.1155/2005/251068.
24. Kim MJ, Jung HS, Hwang-Bo Y, et al. Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetologica. 2013;50(4):505–10. doi:10.1007/s00592-011-0302-0.
25. Stettler C, Stahl M, Allemann S, et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care. 2008;31(8):1534–5. doi:10.2337/dc08-0385.
26. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients: Response to Schindhelm et al. Diabetes Care. 31(11):e90–e90. doi:10.2337/dc08-1491.
27. Wang Y, Zhang YL, Wang YP, et al. A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China: 1,5-AG, hyperglycaemic excursions Diabetes Metab Res Rev. 2012;28(4):357–62. doi:10.1002/dmrr.2278.
28. Yoo HY, Kwak BO, Son JS, et al. Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes. Ann Pediatr Endocrinol Metab 2015;20(4):192-7. doi:10.6065/apem.2015.20.4.192.